COMPOUNDS / METABOLIC / RETATRUTIDE
METABOLIC
RETATRUTIDE
MEDIUM RISK
Medications / Metabolic
BEST FOR:Weight Loss●●●●●●●●○○8/10
RETATRUTIDE · LY3437943 · LY-3437943
GLP-1ObesityDiabetesTriple AgonistInvestigational
Triple GLP-1/GIP/glucagon receptor agonist under investigation for obesity and type 2 diabetes.
— QUICK REFERENCE
ROUTE / DOSAGE
LOW1mg
STANDARD4-8mg
HIGH12mg
Note: Once weekly subcutaneous injection; titrate from 2mg starting dose to mitigate GI side effects
CYCLE
Once weekly subcutaneous injection
BIOAVAILABILITY
~60-70% subcutaneous
ACTIVE DURATION
7 days (subjective)
STORAGE
Refrigerate at 2-8°C
protect from light
do not freeze
HALF-LIFE
~60h (plasma)
DURATION BREAKDOWN
Total7 days
Onset12-24h
Come up1-2 days
Peak2-3 days
Offset2-3 days
After effects1-2 days
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Significant dose-dependent weight loss
Reduced HbA1c and improved glycemic control
Delayed gastric emptying
Reduced food intake and appetite suppression
Improved liver steatosis markers
Potential improvement in cardiovascular risk factors
§ 02 — RISKS
Dose-dependent increases in heart rate peaking at 24 weeks
Gastrointestinal adverse events including nausea, vomiting, and diarrhea
Two deaths reported in Phase 3 trial group (assessed as unrelated to study drug)
Study discontinuation due to adverse events in 2-5% of retatrutide recipients
Long-term safety profile not yet fully established
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE
Phase 2 and Phase 3 clinical trials demonstrate significant dose-dependent weight loss up to 24.2% at 48 weeks with 12mg and HbA1c reductions up to 2.02% at 24 weeks in adults with obesity and type 2 diabetes. Common adverse events are primarily gastrointestinal, dose-related, and mostly mild to moderate in severity. Dose-dependent increases in heart rate were observed, peaking at 24 weeks and declining thereafter. Long-term safety data from ongoing Phase 3 TRIUMPH trials is not yet available, and the quality of weight loss beyond BMI reduction requires further investigation.
§ 06 — SOURCES
[2]
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
pubmed.ncbi.nlm.nih.gov ↗[3]
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
pubmed.ncbi.nlm.nih.gov ↗[4]
The power of three: Retatrutide's role in modern obesity and diabetes therapy
pubmed.ncbi.nlm.nih.gov ↗[5]
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes (TRANSCEND-T2D-1): a phase 3 trial
pubmed.ncbi.nlm.nih.gov ↗[6]
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial
pubmed.ncbi.nlm.nih.gov ↗Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT